CORNELL UNIVERSITY Sample Clauses

CORNELL UNIVERSITY. By: By: [Authorized Signature] [Authorized Signature] Print: Print: Title: Title: Date: Date: ROYALTY REPORT PLANTS/SEED Company Name: CTL Agreement No.: Your Reference No.: Reporting Period (mm/dd/yyyy) From / / Through / / Sales Inside New York State Sales Outside of New York State Annual Sales (A) (B) (C) (D) (E) (F) (G) (H) Licensed Line/Variety CTL Docket No./Contract No. Do you wish to continue licensing this material? Y/N* # Plant Units Sold if applicable Sale Price Per Unit Seed Sales ($) if applicable Royalty Rate Total ($) Royalty Due (AxC) and/or (BxC) # Plant Units Sold if applicable Sale Price Per Unit Seed Sales ($) if applicable Royalty Rate Total ($) Royalty Due (ExG) and/or (FxG) Total Plant Units Sold (A+E) Total Seed Sales (B+F) Total Due for this Line/Variety (D+H) OTHER VARIETIES/DOCKETS: Total Payment Enclosed: * If you answer No, a Termination Notice will follow within a few weeks of receipt of this report. During this time have any of the following occurred: Description (Additional attachments may be included, if space is limited): Type(s) and number(s) of Derived Varieties developed, discovered or isolated during the applicable License Year Sublicenses granted and the name and address of each Sublicensee. Please submit copies of sublicenses, if required in agreement. Register of trees planted of the Licensed Variety, including the address and owner of orchards in which the trees were planted, number and types of trees planted, and total hectares planted Detailed description of progress in growing and commercializing the Licensed Product Research and development results and expenditures related to the Licensed Variety and Licensed Products in the applicable License Year Countries in which Licensee has one or more pending or granted registrations on National List(s) for commercial activities with respect to Licensed Products Detailed description of the promotion and marketing efforts made to maximize sales of Licensed Products in the Territory during the applicable License Year Issues encountered in commercializing the Licensed Products Report Prepared & Approved By: Name (Please Print) Email Signature Date (mm/dd/yyyy) / /
Sample 1Sample 2Sample 3See All (6)
AutoNDA by SimpleDocs
CORNELL UNIVERSITY. By: By: [Authorized Signature] [Authorized Signature] Print: Print: Title: Title: Date: Date: ROYALTY REPORT PLANTS/SEED Company Name CTL Agreement No. Your Reference No. Reporting Period (mm/dd/yyyy) From / / Through / / Sales Inside New York State Sales Outside of New York State Annual Sales (A) (B) (C) (D) (E) (F) (G) (H) Licensed Line/Variety CTL Docket No./Contract No. Do you wish to continue licensing this material?Y/N* # Plant Units Sold if applicable Sale Price Per Unit # Seed Sales if applicable Royalty Rate Total ($) Royalty Due (AxC) and/or (BxC) # Plant Units Sold if applicable Sale Price Per Unit Seed Sales ($) if applicable Royalty Rate Total ($) Royalty Due (ExG) and/or (FxG) Total Plant Units Sold (A+E) Total Seed Sales (B+F) Total Due for this Line/Variety (D+H) * If you answer No, a Termination Notice will follow within a few weeks of receipt of this report. Total Payment Enclosed Report Prepared & Approved By Name (Please Print) Email Signature Date (mm/dd/yyyy) / /
Sample 1Sample 2Sample 3See All (4)
CORNELL UNIVERSITY. Technical Representative(s)
Sample 1Sample 2
CORNELL UNIVERSITY. Ivy League Agreement This is the text of the mutual agreement between the eight Ivy League institutions: Brown University, Columbia College, Cornell University, Dartmouth College, Harvard University, University of Pennsylvania, Princeton University, Yale University. Ivy League Agreement | Dartmouth Admissions A consortium agreement is a contract between a matriculated, Cornell undergraduate, her or his Cornell college registrar, and the registrar of a host college or university.
Sample 1
CORNELL UNIVERSITY. By: Tracyi.c!:ry(Aui12,2019) Name: Xxxxx X. Xxxx XXXXXXX XXXX FOUNDATION By: -:;.is,_::;, �c___. Name: Xxxx Xxxxxxx Title: Associate Vice President for Operations Aug 22, 2019 Title: Executive Director .2 ti I 1 Date: By:_t- p ti-<----. Date: _ ---�J-/-1 -I.�----------- Name: Xxxxxxxx X. Xxxxxxxxx Title: Vice Xxxxxxx for Research/Vice President for Technology Transfer, Intellectual Property, and Research Policy Date: Aug 28, 2019 ATTACHMENT A Cornell University Proposal to Support the Cornell Program in Infrastructure Policy The Prngram's Mission The Cornell Program in Infrastructure Policy (CPIP) is focused on improving the delivery, maintenance, and operation of physical infrastructure.
Sample 1
CORNELL UNIVERSITY. By: Xxxxx Xxxxxxxx Capital Advisors, L.P., as its Advisor By: /s/ Xxxxx Xxxxxxxxxx Xxxxx Xxxxxxxxxx General Counsel FIRST ENERGY NUCLEAR GENERATION CORP. By: Xxxxx Xxxxxxxx Capital Advisors, L.P., as its Manager By: /s/ Xxxxx Xxxxxxxxxx Xxxxx Xxxxxxxxxx General Counsel TOLEDO EDISON COMPANY By: Xxxxx Xxxxxxxx Capital Advisors, L.P., as its Manager By: /s/ Xxxxx Xxxxxxxxxx Xxxxx Xxxxxxxxxx General Counsel XXXXX XXXXXXXX CAPITAL ADVISORS, L.P. By: /s/ Xxxxx Xxxxxxxxxx Xxxxx Xxxxxxxxxx General Counsel KA FIRST RESERVE, LLC By: KA Fund Advisors, LLC, as Manager By: /s/ Xxxxx X. Xxxxx Xxxxx X. Xxxxx Managing Director XXXXX XXXXXXXX MLP INVESTMENT COMPANY By: KA Fund Advisors, LLC, as Manager By: /s/ Xxxxx X. Xxxxx Xxxxx X. Xxxxx Managing Director XXXXX XXXXXXXX ENERGY TOTAL RETURN FUND, INC. By: KA Fund Advisors, LLC, as Manager By: /s/ Xxxxx X. Xxxxx Xxxxx X. Xxxxx Managing Director XXXXX XXXXXXXX MIDSTREAM/ENERGY FUND, INC. By: KA Fund Advisors, LLC, as Manager By: /s/ Xxxxx X. Xxxxx Xxxxx X. Xxxxx Managing Director XXXXX XXXXXXXX ENERGY DEVELOPMENT COMPANY By: KA Fund Advisors, LLC, as Manager By: /s/ Xxxxx X. Xxxxx Xxxxx X. Xxxxx Managing Director NATIONWIDE MUTUAL INSURANCE COMPANY By: /s/ Xxxxx X. Vergance, Jr. Xxxxx X. Xxxxxxxx, Xx. Vice President XXXXX XXXXXX PARTNERS, L.P. By: Xxxxxx Capital Corp., its general partner By: /s/ Xxxxx X. Xxxxxx Xxxxx X. Xxxxxx President XXXXXXX FAMILY INVESTMENTS, LLC By: /s/ Xxxxx X. Xxxxx Xxxxx X. Xxxxx Managing Director THE NORTHWESTERN MUTUAL LIFE INSURANCE COMPANY By: /s/ Xxxx X. Xxxxxxx Xxxx X. Xxxxxxx Its Authorized Representative Signature Page to Unit Purchase Agreement EAGLE INCOME APPRECIATION PARTNERS, L.P. By: Eagle Income Appreciation GP, LLC, its General Partner By: Eagle Global Advisors, LLC, its Managing Member By: /s/ Xxxxxx Day Xxxxxx Day Partner EAGLE INCOME APPRECIATION II, L.P. By: Eagle Income Appreciation GP, LLC, its General Partner By: Eagle Global Advisors, LLC, its Managing Member By: /s/ Xxxxxx Day Xxxxxx Day Partner Signature Page to Unit Purchase Agreement Tortoise Energy Infrastructure Corporation By: /s/ Xxxxxxx X. Xxxxx Xxxxxxx X. Xxxxx President Tortoise Energy Capital Corporation By: /s/ Xxxxxxx X. Xxxxx Xxxxxxx X. Xxxxx President Tortoise MLP Fund, Inc. By: /s/ Xxxxxxx X. Xxxxx Xxxxxxx X. Xxxxx President Tortoise North American Energy Corporation By: /s/ Xxxxxxx X. Xxxxx Xxxxxxx X. Xxxxx Senior Vice President FIDUCIARY/CLAYMORE MLP OPPORTUNITY FUND By: /s/ Quinn T. Xxxxx Xxxxx X. Xxxxx...
Sample 1

Related to CORNELL UNIVERSITY

  • Collaboration Management Promptly after the Effective Date, each Party will appoint a person who will oversee day-to-day contact between the Parties for all matters related to the management of the Collaboration Activities in between meetings of the JSC and will have such other responsibilities as the Parties may agree in writing after the Effective Date. One person will be designated by Merck (the “Merck Program Director”) and one person will be designated by Moderna (the “Moderna Program Director,”) together will be the “Program Directors”. Each Party may replace its Program Director at any time by notice in writing to the other Party. Any Program Director may designate a substitute to temporarily perform the functions of that Program Director by written notice to the other Party. The initial Program Directors will be: For Moderna: [***] For Merck: [***]

  • Principal Investigator The research will be under the direction of (“Principal Investigator”). If, for any reason, he/she is unable to continue to serve as Principal Investigator and a successor acceptable to both UHD and Sponsor is not available, this Agreement shall be terminated as provided in Section 7.

  • Technology License 4.1 Unless any event described in Article 2.2 or 2.3 of this Agreement occurs, all of the technology required to be licensed for any of Party B’s business shall be provided by Party A on an exclusive basis. Party A will try its best to license Party B to use the technology owned by Party A, or re-license Party B to use the technology as approved by the owner.

  • Research Independence The Company acknowledges that each Underwriter’s research analysts and research departments, if any, are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and that such Underwriter’s research analysts may hold and make statements or investment recommendations and/or publish research reports with respect to the Company and/or the offering that differ from the views of its investment bankers. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against such Underwriter with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be different from or inconsistent with the views or advice communicated to the Company by such Underwriter’s investment banking divisions. The Company acknowledges that the Representative is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short position in debt or equity securities of the Company.

  • Technology Transfer Subject to the terms of the Development Supply Agreement, as soon as reasonably practicable, but in no event later than the fifth (5th) anniversary of the Effective Date, Alnylam shall initiate a technology transfer to MedCo, or to its Third Party manufacturer(s) of Licensed Product, selected by MedCo and reasonably acceptable to Alnylam, of Alnylam Know-How that is reasonably necessary or useful for the Manufacture of the Licensed Product, and shall make available its personnel on a reasonable basis to consult with MedCo or such Third Party manufacturer(s) with respect thereto, all at MedCo’s expense, including the Costs reasonably incurred by Alnylam in connection with such technology transfer activities. MedCo shall reimburse Alnylam such Costs incurred with respect to such Manufacturing technology transfer within [***] days after receipt of an invoice therefor. Alnylam and its Affiliates shall keep complete and accurate records in sufficient detail to enable the payments payable hereunder to be determined. Alnylam shall not be required to perform technology transfer to more than one Third Party manufacturer for each stage of the Licensed Product supply chain (i.e., Bulk Drug Substance, Bulk Drug Product and Finished Product). Promptly after MedCo’s written request, Alnylam shall use Commercially Reasonable Efforts to assign to MedCo any manufacturing agreement between Alnylam and a Third Party that is solely related to the manufacture of Licensed Products. Such assignment shall be subject to the terms and conditions of such agreement, including any required consents of such Third Party and MedCo’s written agreement to assume all the obligations of Alnylam under such agreement to be undertaken after such assignment, but Alnylam shall remain solely responsible for its obligations under such agreement arising prior to such assignment. Except as provided in the immediately preceding sentence, MedCo shall be solely responsible for contracting with such Third Party manufacturer (and any other Third Party manufacture to whom Alnylam has initiated technology transfer as set forth in this Section 5.3) for the supply of such Licensed Product and Alnylam shall have no obligations under such agreement between MedCo and such Third Party manufacturer. Alnylam shall use Commercially Reasonable Efforts to obtain any such consent in a form reasonably acceptable to MedCo.

  • Research Support opioid abatement research that may include, but is not limited to, the following:

  • Services to the Corporation Agent will serve, at the will of the Corporation or under separate contract, if any such contract exists, as a director of the Corporation or as a director, officer or other fiduciary of an affiliate of the Corporation (including any employee benefit plan of the Corporation) faithfully and to the best of his ability so long as he is duly elected and qualified in accordance with the provisions of the Bylaws or other applicable charter documents of the Corporation or such affiliate; provided, however, that Agent may at any time and for any reason resign from such position (subject to any contractual obligation that Agent may have assumed apart from this Agreement) and that the Corporation or any affiliate shall have no obligation under this Agreement to continue Agent in any such position.

Time is Money Join Law Insider Premium to draft better contracts faster.